Global Flourescent In Situ Hybridization (FISH) Probe Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Flourescent In Situ Hybridization (FISH) Probe Market Analysis

The fluorescent in situ hybridization (FISH) probe market is experiencing robust growth due to advancements in molecular diagnostics and an increased emphasis on genetic research. FISH probes, essential for detecting and localizing specific DNA or RNA sequences within cells, are pivotal in areas such as cancer diagnostics, genetic disorders, and prenatal screening. Recent developments include the enhancement of probe specificity and sensitivity, enabling more accurate and reliable results. For instance, the introduction of multiplex FISH probes allows simultaneous detection of multiple targets, improving diagnostic efficiency and reducing analysis time. Furthermore, the integration of FISH technology with next-generation sequencing (NGS) and digital imaging systems is expanding its applications and accuracy. The market is also benefiting from growing research funding and technological innovations, which are driving the development of new and improved FISH probes. As personalized medicine and genomic research continue to advance, the FISH probe market is set to expand, driven by increasing demand for precise diagnostic tools and advancements in molecular biology techniques.

Flourescent In Situ Hybridization (FISH) Probe Market Size

The global flourescent in situ hybridization (FISH) probe market size was valued at USD 883.28 million in 2023 and is projected to reach USD 1,472.84 million by 2031, with a CAGR of 6.60% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Flourescent In Situ Hybridization (FISH) Probe Market Trends

“Rise in Customizable FISH Probes”

The fluorescent in situ hybridization (FISH) probe market is expanding rapidly due to the increasing demand for precise genetic and cellular analysis. A notable trend driving such growth is the rise of customizable FISH probes tailored to specific research needs. For instance, companies such as Abbott and Agilent Technologies are offering bespoke FISH probes that target unique genetic sequences, enhancing the accuracy and specificity of genetic research. Such customization allows researchers to conduct more detailed studies on genetic abnormalities and complex diseases. The ability to create targeted probes facilitates advancements in cancer research, as exemplified by recent studies using customized FISH probes to identify rare genetic mutations in tumor cells. Such developments are propelling the FISH probe market forward, providing researchers with more effective tools for genetic and molecular analysis.

Report Scope and Flourescent In Situ Hybridization (FISH) Probe Market Segmentation

Flourescent In Situ Hybridization (FISH) Probe Market Definition

Fluorescent in situ hybridization (FISH) probe refers to a molecular tool used in the FISH technique to detect and localize specific nucleic acid sequences within cells or tissue samples. These probes are labeled with fluorescent dyes and are designed to hybridize, or bind, to complementary DNA or RNA sequences in the sample. When the probe binds to its target sequence, it emits fluorescence upon exposure to a specific wavelength of light, allowing researchers to visualize and analyze the presence, location, and quantity of specific genes or genetic abnormalities. FISH probes are widely used in genetic research, diagnostics, and clinical applications to study chromosomal abnormalities, gene expression, and cellular structures.

Flourescent In Situ Hybridization (FISH) Probe Market Dynamics

Drivers

• Rising Incidence of Genetic Disorders

The rising incidence of genetic disorders significantly boosts the demand for fluorescent in situ hybridization (FISH) probes, which are crucial for precise diagnosis and research. For instance, the American Cancer Society reported that in 2023, approximately 1.9 million new cancer cases were diagnosed in the U.S., with many requiring detailed genetic analysis to guide treatment strategies. FISH probes play a vital role in detecting chromosomal abnormalities such as HER2 gene amplification in breast cancer or identifying specific genetic mutations in leukemia, enabling targeted therapies. Additionally, the increasing prevalence of congenital disorders, such as Down syndrome and Turner syndrome, further drives the need for FISH probes, as they allow for early and accurate detection of chromosomal abnormalities in prenatal and postnatal screenings. The growing burden of such genetic conditions highlights the importance of advanced diagnostic tools such as FISH probes in improving patient outcomes and advancing research.

• Expanding Clinical Applications

The expanding clinical applications of FISH probes are significant drivers of market growth. In oncology, FISH probes are crucial for detecting genetic abnormalities such as the BCR-ABL translocation in chronic myeloid leukemia (CML), aiding in precise diagnosis and treatment planning. This usage supports the growing demand for FISH technology in cancer diagnostics. Similarly, in prenatal screening, FISH probes are used to identify chromosomal abnormalities, such as those linked to Down syndrome, early in pregnancy. Such capability enhances early detection and informed decision-making, broadening the application of FISH technology in reproductive health. These applications not only highlight the importance of FISH probes but also contribute to their increasing market demand, driving overall growth in the sector.

Opportunities

• Expansion in Clinical Diagnostics

Expansion in clinical diagnostics presents a substantial opportunity for fluorescent in situ hybridization (FISH) probes, driven by the growing need for accurate and reliable diagnostic tools. For instance, FISH probes are increasingly utilized in the diagnosis and management of various cancers, such as breast cancer, where they help identify HER2 gene amplifications, a key marker for targeted therapies. Similarly, FISH probes are employed in diagnosing genetic disorders such as Down syndrome through prenatal screenings, offering early and accurate detection of chromosomal abnormalities. The integration of FISH technology in such clinical settings not only enhances diagnostic accuracy but also supports personalized treatment plans, highlighting its growing role in modern medical diagnostics. Consequently, fostering the flourescent in situ hybridization (FISH) probe market.

• Increasing in Research Funding

Increased research funding in genomic and cancer studies is significantly enhancing the opportunities for fluorescent in situ hybridization (FISH) probes to be utilized in advanced research and clinical trials. For instance, the National Cancer Institute's (NCI) investment in cancer genomics research has led to the development of new FISH probe technologies that are crucial for understanding complex genetic mutations in various cancers. Similarly, large-scale genomic studies funded by organizations such as the Wellcome Trust have employed FISH probes to investigate genetic variations associated with rare diseases, accelerating the discovery of biomarkers and potential treatment pathways. Such increased funding not only supports the advancement of FISH technology but also expands its application in cutting-edge research and clinical trials, driving innovation and improving patient outcomes.

Restraints/Challenges

• Regulatory and Quality Control Challenges

Regulatory and quality control challenges in the FISH probe market involve navigating complex and region-specific regulations to ensure compliance and maintain high standards. For instance, in Europe, the CE marking process mandates compliance with the in vitro diagnostic devices directive (IVDD) or the newer in vitro diagnostic regulation (IVDR), which involves demonstrating conformity to specific quality management standards and clinical evidence requirements. Such regulatory variations require manufacturers to adapt their quality control and documentation practices to meet the different standards, adding complexity to market entry and product management.

• Limited Sensitivity and Resolution

Limited Sensitivity and Resolution in fluorescent in situ hybridization (FISH) probes can pose significant challenges in advanced research and clinical diagnostics. For instance, FISH may struggle to detect low-abundance genetic targets, such as rare mutations in early-stage cancers, where only a small proportion of cells exhibit the mutation. In April 2023, according to a study published in National Library of Medicine, researchers reported difficulties in using FISH to identify low-level HER2 gene amplifications in breast cancer, which are critical for determining appropriate treatment. The study found that the limited resolution of FISH probes could miss these subtle genetic changes, leading to potential underdiagnosis or misdiagnosis.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Flourescent In Situ Hybridization (FISH) Probe Market Scope

The market is segmented on the basis of technology, type, application, and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Q FISH
• FLOW FISH
• Others

Type

• DNA
• RNA
  • mRNA
  • miRNA
  • Other

Application

• Cancer Research
  • Lung
  • Breast
  • Bladder
  • Hematological
  • Gastric
  • Prostrate
  • Cervical
  • Other
• Genetic Diseases
• Other

End-User

• Research
• Clinical
• Companion Diagnostics

Flourescent In Situ Hybridization (FISH) Probe Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, technology, type, application, and end-users.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America led the market in revenue share, primarily due to the region's high incidence of genetic abnormalities, which contribute to birth defects, developmental disabilities, and various metabolic disorders. The substantial prevalence of these conditions drives demand for advanced diagnostic and therapeutic solutions. Additionally, increased awareness and investment in genetic research and healthcare infrastructure further support market growth in this region.

Asia-Pacific region is anticipated to experience substantial growth from 2024 to 2031, driven by an increasing prevalence of cytogenetic-based diseases and expanding research and development efforts. The rise in chronic and genetic disorders in this region is fueling demand for advanced diagnostic technologies. Additionally, increased investment in R&D by both public and private sectors is further accelerating market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Flourescent In Situ Hybridization (FISH) Probe Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Flourescent In Situ Hybridization (FISH) Probe Market Leaders Operating in the Market Are:

• Abnova Corporation (U.S.)
• Agilent Technologies Inc. (U.S.)
• Biocare Medical LLC (U.S.)
• LGC Biosearch Technologies (U.S.)
• Creative BioLabs (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Genemed Biotechnologies Inc. (U.S.)
• Merck KGaA (Germany)
• Oxford Gene Technology IP Limited (U.K.)
• PerkinElmer (U.S.)
• QIAGEN (Germany)
• BioDot (U.S.)
• Bio-Techne (U.S.)
• BioGenex (U.S.)

Latest Developments in Flourescent In Situ Hybridization (FISH) Probe Market

• In July 2023, KromaTiD, a company specializing in single-cell analysis tools for cell and gene therapy research and commercialization, announced the release of more than 300 centromere, telomere, and gene probes for use in its directional Genomic Hybridization (dGH) in-Site assays
• In October 2023, Monte Rosa Therapeutics and F. Hoffmann-La Roche AG entered into a strategic partnership and licensing agreement to collaborate on the discovery and development of molecular glue degraders (MGDs) aimed at treating cancer and neurological disorders

SKU-44767